FDA Meeting on Oxycyte Clinical Trial Scheduled For Oxygen Biotherapeutics, Inc. (OXBO.OB)
Oxygen Biotherapeutics, Inc. (OTCBB: OXBO) announced that it has a meeting scheduled for October with the Food and Drug Administration (FDA) about any remaining issues with a planned trial for its Oxycyte drug. Oxycyte is a perfluorocarbon oxygen carrier. Its proposed use is to help with traumatic brain injury. Oxygen Bio and the FDA, the U.S. medical standards agency, have tentatively set Oct. 20 as the meeting date. “At that meeting, we will be extensively prepared to resolve any remaining issues and concerns the FDA may have,” said company Chairman and CEO Chris J. Stern. “We view this as a…